7,170 reports of this reaction
5.2% of all POMALIDOMIDE reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for POMALIDOMIDE, manufactured by Celgene Corporation. There are 7,170 FDA adverse event reports linking POMALIDOMIDE to FATIGUE. This represents approximately 5.2% of all 136,988 adverse event reports for this drug.
POMALIDOMIDE has an overall safety score of 88 out of 100. Patients taking POMALIDOMIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among POMALIDOMIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for POMALIDOMIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 7,170 FDA reports for POMALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 5.2% of all adverse event reports for POMALIDOMIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking POMALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.